Adherence to Palivizumab Prophylaxis

NCT05778240 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 229

Last updated 2023-03-21

No results posted yet for this study

Summary

The goal of this clinical trial is to analyze implications of two alternative nudge-interventions to increase adherence to palivizumab prophylaxis in children with congenital heart disease. The main questions investigators aim to answer are:

* Are well-established cognitive biases effective in increasing patient families' adherence to the palivizumab prophylaxis program?
* What are the factors that affect families' adherence to the prophylaxis program and whether and how the effects of interventions depend on these factors?

To study these questions investigators planned to utilize four well-established cognitive biases in designing two alternative nudge-interventions and investigators measured the effectiveness of each nudge-intervention against a control group.

Patients were randomly allocated to one control and two treatment groups. In the control group, investigators informed participants about the prophylaxis program and provided a schedule. Patients in the first treatment group were additionally called two days before appointments (status quo bias), and were asked to plan the appointment day (implementation intention). Patients in the second treatment group received biweekly messages informing them about the benefits of the program as well as the current adherence rate (availability bias and social norm).

Conditions

  • Congenital Heart Disease in Children
  • RSV

Interventions

BEHAVIORAL

Phone call

Participants were given the vaccination appointment card and participants received a telephone call every month two days before their appointment. Participants were reminded that they have a set appointment and were asked to plan the day of their appointment as detailed below. The standard script used in the telephone call in every hospital was as follows:Hello, we are calling you because you are enrolled in the palivizumab prophylaxis research program. As you know, you have a vaccination appointment on \[enter date\] at \[enter time\]. To help you plan your day of appointment, we have a few short questions. 1. At your appointment day, will you be coming to the hospital from home, or will you need to get permission from your workplace? 2. What kind of transportation do you plan to take to come to the hospital at your appointment day? 3. At what time do you plan to leave home or work to come to the hospital?

BEHAVIORAL

Text message

Participants were given the vaccination appointment card and participants were included in a messaging group (on Whatsapp or SMS, depending on the participant's preference) where, twice a month they received a message informing them on RSV, on the additional risks caused by RSV infection in children with congenital heart diseases and on the benefits of adherence to the prophylaxis program. These messages also involved statements about the high number of patient families that kept their appointments in the previous month.

BEHAVIORAL

Control

Participants were given the vaccination appointment card.

Sponsors & Collaborators

  • Sabanci University

    collaborator OTHER
  • Maras Necip Fazil City Hospital

    collaborator UNKNOWN
  • Kocaeli University

    collaborator OTHER
  • Van Research and Education Hospital

    collaborator UNKNOWN
  • Sakarya University

    collaborator OTHER
  • Sivas Numune Hospital

    collaborator OTHER_GOV
  • Kosuyolu Heart Hospital

    lead OTHER

Principal Investigators

  • Elif Erolu, M.D.Ph.D. · Kosuyolu Heart Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2020-12-31
Completion
2021-06-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05778240 on ClinicalTrials.gov